Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Tomas Jernberg(Karolinska Institutet), Lars Wallentin(Uppsala University), Hideo Naganuma(Daiichi-Sankyo (Japan)), Christopher D. Payne(Eli Lilly (United States)), Kenneth J. Winters(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Christelle Darstein(Novartis (Switzerland)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Agneta Siegbahn(Uppsala University)
European Heart Journal
April 18, 2006
10.1093/eurheartj/ehi877
Cited by 537

Related Papers

Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
|The Lancet|2010|1k
Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study
|European Heart Journal|2019|897